Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Solid Tumor, Adult 1 Neurofibromatosis 1 1 Neurofibroma 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Breast Neoplasms 1

Interventions

Lovastatin 3 Deoxycholic Acid 3 AZD 6244 3 pirfenidone 2 Vinblastine 2 Transcranial Direct Current Stimulation 2 Sirolimus 2 Polidocanol 2 Lasers, Solid-State 2 Inhalation 2 Acetylcysteine 2 tipifarnib 1 pomalidomide 1 peginterferon alfa-2b 1 mirdametinib 1 diphenylcyclopropenone 1 binimetinib 1 X-Rays 1 Vincristine 1 Temozolomide 1 Surveys and Questionnaires 1 Sunitinib 1 Specimen Handling 1 Sorafenib 1 Saline Solution 1 Ranibizumab 1 Radiotherapy 1 Photons 1 Pharmacokinetics 1 Neuropsychological Tests 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurofibromatosis 1 × mirdametinib × Clear all

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡